Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Phase II Trial of Single-Agent Nivolumab in Patients With Microsatellite Unstable/Mismatch Repair Deficient/Hypermutated Uterine Cancer

NCT03241745 is registered in ClinicalTrials.gov with Memorial Sloan Kettering Cancer Center as lead sponsor.

NCT NCT03241745
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT03241745 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Phase II Trial of Single-Agent Nivolumab in Patients With Microsatellite Unstable/Mismatch Repair Deficient/Hypermutated Uterine Cancer
Lead sponsor
Memorial Sloan Kettering Cancer Center
Phase
Phase 2
Overall status
Completed
Start date
August 3, 2017
Completion date
April 1, 2024
Enrollment
35 (actual)
Sites
8

Conditions

As the registry lists them; a condition with its own page is linked.

carcinosarcoma, clear cell carcinoma, endometrial carcinoma, high grade endometrial stromal sarcoma, leiomyosarcoma, undifferentiated sarcoma, uterine cancer